Charles Dumontet

Oncology · 2006–2023

A researcher in the Science corpus: 7 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Charles Dumontet trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. M. Jordan

Papers from Charles Dumontet's perspective

Ordered by how strongly the researchers Charles Dumontet trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (Cancer Research)
  2. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the… (Journal of Clinical Oncology)
  3. Microtubules as a target for anticancer drugs (Nature Reviews. Cancer)
  4. Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies (Clinical Cancer Research)
  5. Disrupting tumour blood vessels (Nature Reviews. Cancer)
  6. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. (Journal of Clinical Oncology)
  7. Present and Future
  8. Current Status and Future Directions
  9. Arming antibodies: prospects and challenges for immunoconjugates (Nature Biotechnology)
  10. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. (Clinical Cancer Research)

Their papers